Efficacy and safety of durvalumab with or without tremelimumab in the treatment of metastatic non-small cell lung cancer: a meta-analysis of randomized controlled trials.
The therapeutic role of combining PD-L1 and CTLA-4 blockade in metastatic non-small cell lung cancer (NSCLC) remains unclear, with individual trials yielding discrepant results. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the efficacy and safety of durvalumab with or without tremelimumab in advanced NSCLC.
The therapeutic role of combining PD-L1 and CTLA-4 blockade in metastatic non-small cell lung cancer (NSCLC) remains unclear, with individual trials yielding discrepant results. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the efficacy and safety of durvalumab with or without tremelimumab in advanced NSCLC.
What the study was
- Study design
- Meta-Analysis
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Proc (Bayl Univ Med Cent)
Why it surfaced
Matched watchlist topic 'Precision oncology and genomic medicine'. Study design: Meta-Analysis. Score: 8/10 (N:1, R:3, D:2, P:2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.